Product Labelling. (a) During the Exclusive Period, the Labelling shall, if Schering elects to use the ICN Trademark, contain the ICN Trademark and shall otherwise be consistent in format (but not substance) with the Labelling for Schering's other pharmaceutical products sold in the corresponding country within the Territory at the time in question. Unless prohibited by applicable law, if Schering elects to use the ICN Trademark, the Labelling shall indicate that the Product is under license from ICN. (b) To the extent Schering elects to use the ICN Trademark, Schering shall not change the Labelling in format (but not substance) during the Exclusive Period without the prior written authorization of ICN (which shall not be unreasonably withheld), except that ICN's consent is not required if Schering, at its own cost and expense, desires to change the colors and other elements of trade dress to conform to the trade dress of Schering's other pharmaceutical products, provided that such change does not affect the other applicable Labelling requirements of this Section 5.2.
Appears in 7 contracts
Samples: Exclusive License and Supply Agreement (Icn Pharmaceuticals Inc), Exclusive License and Supply Agreement (Ribapharm Inc), Exclusive License and Supply Agreement (Icn Pharmaceuticals Inc)